Document Detail


F2A sequence linking MGMT(P140K) and MDR1 in a bicistronic lentiviral vector enables efficient chemoprotection of haematopoietic stem cells.
MedLine Citation:
PMID:  23037811     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Chemoprotection of haematopoietic stem cells (HSCs) by gene therapeutic transfer of drug-resistance genes represents the encouraging approach to prevent myelosuppression, which is one of the most severe side effects in tumor therapy. Thus, we cloned and evaluated six different bicistronic lentiviral SIN vectors encoding two transgenes, MGMT(P140K) (an O(6)-benzylguanine-resistant mutant of methylguanine-DNA methyltransferase) and MDR1 (multidrug resistance 1), using various linker sequences (IRESEMCV, IRESFMDV and 2A-element of FMDV (F2A)). Expression of both transgenes in HL-60 and in K562 cells was assayed by quantitative real-time PCR. Combination therapy with ACNU plus paclitaxel in HL-60 cells and with carmustin (BCNU) plus doxorubicin in K562 cells resulted in the most significant survival advantage of cells transduced with the lentiviral vector HR'SIN-MGMT(P140K)-F2A-MDR1 compared with untransduced cells. In human HSCs, overexpression of both transgenes by this vector also caused significantly increased survival and enrichment of transduced cells after treatment with BCNU plus doxorubicin or temozolomide plus paclitaxel. In summary, we could show significant chemoprotection by overexpression of MDR1 and MGMT(P140K) with a lentiviral vector using the F2A linker element in two different haematopoietic cell lines and in human primary HSCs with various combination regimens. Consequently, we are convinced that these in vitro investigations will help to improve combination chemotherapy regimens by reducing myelotoxic side effects and increasing the therapeutic efficiency.Cancer Gene Therapy advance online publication, 5 October 2012; doi:10.1038/cgt.2012.67.
Authors:
P Maier; D Heckmann; I Spier; S Laufs; M Zucknick; H Allgayer; S Fruehauf; W J Zeller; F Wenz
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-05
Journal Detail:
Title:  Cancer gene therapy     Volume:  19     ISSN:  1476-5500     ISO Abbreviation:  Cancer Gene Ther.     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-5     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9432230     Medline TA:  Cancer Gene Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  802-810     Citation Subset:  -    
Affiliation:
1] Department of Radiation Oncology, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany [2] Pharmacology of Cancer Treatment, DKFZ (German Cancer Research Center), Heidelberg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Decidua mesenchymal stem cells migrated toward mammary tumors in vitro and in vivo affecting tumor g...
Next Document:  East versus West: Organic contaminant differences in brown pelican (Pelecanus occidentalis) eggs fro...